EGFR-targeted therapies in the post-genomic era.
Cancer Metastasis Rev
; 36(3): 463-473, 2017 09.
Article
in En
| MEDLINE
| ID: mdl-28866730
ABSTRACT
Over 90% of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. Therapies targeting EGFR include monoclonal antibodies, tyrosine kinase inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and antisense gene therapy. Few EGFR-targeted therapeutics are approved for clinical use. The monoclonal antibody cetuximab is a Food and Drug Administration (FDA)-approved EGFR-targeted therapy, yet has exhibited modest benefit in clinical trials. The humanized monoclonal antibody nimotuzumab is also approved for head and neck cancers in Cuba, Argentina, Colombia, Peru, India, Ukraine, Ivory Coast, and Gabon in addition to nasopharyngeal cancers in China. Few other EGFR-targeted therapeutics for head and neck cancers have led to as significant responses as seen in lung carcinomas, for instance. Recent genome sequencing of head and neck tumors has helped identify patient subgroups with improved response to EGFR inhibitors, for example, cetuximab in patients with the KRAS-variant and the tyrosine kinase inhibitor erlotinib for tumors harboring MAPK1E322K mutations. Genome sequencing has furthermore broadened our understanding of dysregulated pathways, holding the potential to enhance the benefit derived from therapies targeting EGFR.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
ErbB Receptors
/
Head and Neck Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Cancer Metastasis Rev
Journal subject:
NEOPLASIAS
Year:
2017
Type:
Article
Affiliation country:
United States